title: The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients.
abstract: OBJECTIVE
  We sought to examine the utility of serum albumin measurement in staging AIDS and monitoring patients' response to therapy.
  
  
  METHODS
  The possible importance of serum albumin measurement in assessing AIDS stage and in monitoring the response to highly active antiretroviral therapy using CD4 cell count and body weight as parameters was examined in 185 consecutive HIV-infected, therapy-naïve individuals who were recruited for antiretroviral therapy at the university of Ilorin Teaching Hospital. The regimen included lamivudine, stavudine and nevirapine. The diagnosis of AIDS was established through a combination of clinical features and HIV seropositivity using two different enzyme-linked immunosorbent assay techniques. Serum albumin level was determined by the Bromocresol green method, while the CD4 lymphocyte count was obtained using the Dynal T4 count method. Body weight was measured in kilograms with light clothes on.
  
  
  RESULTS
  There were significant positive correlations between pretreatment albumin and both pretreatment CD4 cell count and pretreatment weight, and between post-treatment albumin and both post-treatment weight and post-treatment CD4 cell count up to a count of 700 cells/microL. There were also significant positive correlations between increase in serum albumin and both increase in body weight and duration of treatment.
  
  
  CONCLUSIONS
  We conclude that, in developing countries where many patients may not be able to afford to pay for CD4 cell counts and viral load tests, which are the traditional markers for HIV disease, serum albumin would be a very useful surrogate test for predicting severity of HIV infection and for clinical monitoring of response to antiretroviral therapy.
authors.affiliation: Department of Haematology and Blood Transfusion, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
authors.forename: H O
authors.initials: HO
authors.lastname: Olawumi
authors.forename: P O
authors.initials: PO
authors.lastname: Olatunji
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001835:Body Weight; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000627:therapeutic use; D011237:Predictive Value of Tests; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012680:Sensitivity and Specificity; D012709:Serum Albumin / Q000032:analysis* / Q000378:metabolism; D012720:Severity of Illness Index; D018119:Stavudine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D012709:Serum Albumin; D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine